Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 18, 2026
TickeronGET DAILY SIGNALS
Why Is BillionToOne (BLLN) Stock Down -9.59% Today?

Why Is BillionToOne (BLLN) Stock Down -9.59% Today?

Key Takeaways

  • Shares of BLLN fell 9.59% to $88.15 in early Wednesday trading, down from the prior session's close of $97.50.
  • The primary catalyst is a critical short-seller report from Fuzzy Panda Research, published before the opening bell, alleging improper billing practices and undisclosed state Medicaid scrutiny.
  • Allegations include a Tennessee Medicaid fraud-unit referral, billing through unlisted CPT codes at roughly 10 times standard rates, and carrier screening billed alongside about 88% of prenatal tests.
  • Fuzzy Panda's own modeling claims EBITDA could fall roughly 80% and False Claims Act exposure could exceed $1.2 billion; none of this is established, and the company has not publicly responded.
  • A fragile technical backdrop amplified the drop: the stock was already below its 50-day and 200-day averages and had slumped 8.4% on Monday.
  • Biotech peers and sector ETFs traded higher, confirming the selloff is company-specific rather than a sector move.
  • News Significance Score: 58/100 — Serious but contested short-seller allegations paired with a move 3.6 times the stock's normal daily swing.
  • Investors can dig deeper into Price Targets, Earnings, and Forecast data on Tickeron's dedicated pages.
  • For systematic trading ideas, explore Trending AI Robots.

Opening Summary

BillionToOne, Inc. (BLLN) is a Menlo Park–based molecular diagnostics company whose Quantitative Counting Templates platform powers prenatal screening and the Northstar oncology franchise; it went public in November 2025 and carries a market value of roughly $4.6 billion. On Wednesday the stock slid 9.59% to $88.15, compared with Tuesday's close of $97.50, putting the shares at their lowest level since early September. The direction was decisively negative from the pre-market session onward. The immediate reason cited by the market is a bearish research report from short-seller Fuzzy Panda Research, which disclosed its own short position and alleged problematic reimbursement practices, undisclosed regulatory scrutiny and weak differentiation in the company's cancer tests.

The Short-Seller Report at the Center of the Selloff

The report, circulated before Wednesday's open, leans on state public-records requests, interviews with unnamed former employees and conversations with physicians. Its central claim is that Tennessee's Office of Program Integrity opened an inquiry in 2024 after receiving 11 tips and referred the matter to the Tennessee Bureau of Investigation's Medicaid Fraud Control Division — scrutiny the report says was never disclosed in securities filings. Fuzzy Panda also points to Michigan Medicaid data showing carrier screening billed alongside roughly 88% of non-invasive prenatal tests, and argues patient deductible and copay caps of $99 to $349 were applied without income verification.

Two features of the report explain why the market reaction was sharp. First, it attacks the durability of revenue rather than a single quarter, arguing that curbing what it calls excess carrier-screening claims could cut EBITDA by about 80%. Second, it puts a headline number on legal risk, modeling hypothetical False Claims Act penalties above $1.2 billion — more than a quarter of the company's market capitalization. That figure is the firm's own estimate, and a law-enforcement referral does not establish wrongdoing or the filing of charges. BillionToOne has not publicly addressed the allegations.

A Fragile Setup Into the News

The report landed on a stock that was already under distribution. BLLN peaked near $150 in early August, slid 38.9% in a single session on August 6, and then rallied back toward $115 by late October before rolling over again. Coming into Wednesday, the shares had dropped 5.1% on November 13 and 8.4% on November 16, breaking below both the 50-day average near $106.90 and the 200-day average near $97.80. That left little technical support beneath Tuesday's close, and momentum indicators had already turned negative before the report existed — a condition that tends to magnify the impact of adversarial research.

Market Context and Trading Activity

Turnover has been running hot relative to history: the two prior sessions each cleared 400,000 shares against a 60-session average of roughly 293,000, and elevated activity has persisted since the November 5 post-earnings session. The move was idiosyncratic. The iShares Biotechnology ETF and the SPDR Biotech ETF were both modestly higher on the day, and peer MYGN gained more than 2%, while NTRA slipped less than 2%. The Nasdaq-100 proxy was fractionally lower. In other words, nothing in the sector tape accounts for a near-10% decline in this name.

News Significance Score

The score runs from 0 — no meaningful news and an ordinary move — to 100, meaning transformative news and an extreme, rare price move. This event lands at 58 out of 100. The verified news is substantial in its own right: a short-seller report alleging undisclosed regulatory scrutiny and challenged reimbursement practices against a $4.6 billion company is material, even though the claims remain unproven and the company has not responded. The price move is unusual but not extreme: 9.59% is about 3.6 times the stock's 2.7% average daily swing, and only two of the last 60 sessions produced an equal or larger absolute change. Moderate news plus a moderately rare move combine into a mid-range score.

What Comes Next for BLLN

The immediate focus is whether BillionToOne issues a formal rebuttal, and whether any state or federal agency confirms or disputes the report's characterization of its billing history. The company's next scheduled milestone is the December 15 commercial launch of Northstar Clear, its tissue-free minimal residual disease test, following third-quarter revenue of $123 million, up 47% year over year, and raised full-year guidance of $460 million to $470 million. Fourth-quarter results and 2027 guidance will be the next hard test of the reimbursement narrative. Risks include further short-seller follow-ups, reimbursement disputes with payers, rising days sales outstanding, heavy insider selling under pre-arranged plans, and the stock's history of double-digit single-session swings. Analysts remain broadly constructive, with most ratings at buy and an average target well above the current price, though those targets now face a credibility test.

Trending AI Robots

Tickeron's Trending AI Robots page curates the platform's strongest current performers from a universe of hundreds of AI trading bots spanning thousands of tickers. Because bots differ widely by strategy, timeframe, performance metrics and traded symbols, the page narrows the field to those best suited to prevailing market conditions. It is a practical starting point for traders who want to see how automated strategies are positioned right now.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BLLN

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Momentum Indicator for BLLN turns negative, indicating new downward trend

BLLN saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator turned negative. In 19 of the 21 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for BLLN turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 10 similar instances when the indicator turned negative. In 9 of the 10 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

BLLN moved below its 50-day moving average on November 13, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for BLLN crossed bearishly below the 50-day moving average on November 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 1 of 2 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 50%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BLLN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

The Aroon Indicator for BLLN entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for BLLN's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +2.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where BLLN advanced for three days, in 48 of 54 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.

BLLN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 43 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. BLLN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.016) is normal, around the industry mean (67.298). BLLN has a moderately high P/E Ratio (136.508) as compared to the industry average of (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (12.195) is also within normal values, averaging (9.775).

The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BLLN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.

Notable companies

The most notable companies in this group are IQVIA Holdings (NYSE:IQV), Illumina (NASDAQ:ILMN), Guardant Health (NASDAQ:GH), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

Market Cap

The average market capitalization across the Medical Specialties Industry is 20.94B. The market cap for tickers in the group ranges from 27 to 4.39T. MKYSF holds the highest valuation in this group at 4.39T. The lowest valued company is FOGCF at 27.

High and low price notable news

The average weekly price growth across all stocks in the Medical Specialties Industry was -8%. For the same Industry, the average monthly price growth was -13%, and the average quarterly price growth was 20%. VCYT experienced the highest price growth at 2%, while IMDX experienced the biggest fall at -33%.

Volume

The average weekly volume growth across all stocks in the Medical Specialties Industry was 3%. For the same stocks of the Industry, the average monthly volume growth was 1% and the average quarterly volume growth was -30%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 52
Price Growth Rating: 51
SMR Rating: 78
Profit Risk Rating: 87
Seasonality Score: 26 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry MedicalSpecialties

Industry
N/A
Address
1035 O’Brien Drive
Phone
+1 650 460-2551
Employees
713
Web
https://www.billiontoone.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.